Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 22Carcinoma, Merkel Cell 4Sarcoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Carcinoma, Squamous Cell 2Carcinoma, Basal Cell 2Skin Neoplasms 1Sezary Syndrome 1Recurrence 1Paget Disease, Extramammary 1Muir-Torre Syndrome 1Microcystic adnexal carcinoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Eccrine Porocarcinoma 1Carcinoma, Signet Ring Cell 1Carcinoma, Basosquamous 1Breast Neoplasms 1Adenocarcinoma, Papillary 1

Interventions

Peripheral Blood Stem Cell Transplantation 23fludarabine phosphate 20Cyclophosphamide 18Mycophenolic Acid 16Whole-Body Irradiation 15Cyclosporine 15Busulfan 12Tacrolimus 11Methotrexate 10Antilymphocyte Serum 9Radiotherapy 8Melphalan 8Etoposide 8pembrolizumab 7Methylprednisolone 6Filgrastim 6Sirolimus 4Prednisone 4Nivolumab 4sargramostim 3Vincristine 3Transplantation 3Therapeutics 3Polymerase Chain Reaction 3Cord Blood Stem Cell Transplantation 3Amplified Fragment Length Polymorphism Analysis 3mogamulizumab 2merphos 2bempegaldesleukin 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × talimogene laherparepvec × Dermatologic × Clear all
NCT02288897 2022-01-19

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Provectus Pharmaceuticals

Phase 3 Terminated
20 enrolled 13 charts
Dermatologic

Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡